SERA - NASDAQ
Sera Prognostics, Inc.
$2.22
+8.3%Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
At a Glance
Live SnapshotSera Prognostics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Sera Prognostics, Inc. Income Statement
SERA • NASDAQ
| Sera Prognostics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
81K | 77K | 306K | 268K | 82K | 25K | 36K | |
GROSS PROFIT | |||||||
(164K) | (82K) | (210K) | (193K) | (37K) | (11K) | (18K) | |
-83K | -5K | 96K | 75K | 45K | 14K | 18K | |
OPERATING INCOME | |||||||
(36.4M) | (36.6M) | (39.9M) | (45.7M) | (35.4M) | (18M) | (16.6M) | |
(23.3M) | (21.9M) | (24.7M) | (31.5M) | (24.4M) | (10.2M) | (7.2M) | |
(13.2M) | (14.7M) | (15.2M) | (14.2M) | (11M) | (7.8M) | (9.4M) | |
-36.5M | -36.6M | -39.8M | -45.7M | -35.4M | -18M | -16.6M | |
PRE-TAX INCOME | |||||||
(9K) | (28K) | (55K) | (61K) | (746K) | (1.8M) | (2M) | |
4.6M | 2.7M | 1.6M | 395K | -601K | -1.8M | -1.9M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -17K | |
4.6M | 3.7M | 3.6M | 1.5M | 386K | -1.9M | 55K | |
-31.9M | -32.9M | -36.2M | -44.2M | -35M | -19.8M | -16.5M | |
NET INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (3.9M) | |
-31.9M | -32.9M | -36.2M | -44.2M | -35M | -19.8M | -20.4M |
SEC Filings
SERA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | May 26, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 18, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 24, 2025 | November 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Related Guides
Continue your SERA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.